This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Charlotte Morabito at CNBC has put together “Why Pharmacies Overcharge,” an entertaining and provocative video on the pharmacy industry and its generic prescription pricing. It’s definitely worth your time. I especially enjoyed the cool visualizations of Drug Channels Institute’s industry data. Links below. The video covers the history of pharmacy, from the “Soda Fountain Era” to “Lick, Stick, and Pour” to the rise of PBMs and GoodRx. .
Annual Drug Patent Expirations for NAPROXEN+SODIUM Naproxen Sodium is a drug marketed by Bionpharma Inc, Catalent, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd,…. The post New patent for Bionpharma Inc drug NAPROXEN SODIUM appeared first on DrugPatentWatch - Make Better Decisions.
Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists from the German Cancer Research Center (DKFZ) and the Medical Faculty Mannheim, Heidelberg University, have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Infectious disease is a leading cause of death globally and bioactivity data against pathogens (fungi, bacteria, viruses, and parasites) is an important category in ChEMBL, especially in light of the ongoing pandemic. In ChEMBL version 29, there are over 2 M bioactivity data points against fungal, bacterial or viral targets (for 460 K compounds) available for pathogen-related research.
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Novartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair ® Breezhaler ® (IND/GLY/MF*) and Atectura ® Breezhaler ® (IND/MF**) — for patients whose asthma is uncontrolled with LABA/ICS^ and ICS, respectively 1,2. Data from post hoc analyses of the Phase III PLATINUM program (including IRIDIUM and ARGON studies) further establish efficacy of Enerzair Breezhaler 3-5.
In this post we explore the different in vitro potency assays for assessing the function of anti-PD-1 checkpoint inhibitors, which are used to test the T cell response of anti-PD-1 (programmed death-1) agents.
Annual Drug Patent Expirations for QUILLICHEW+ER Quillichew Er is a drug marketed by Nextwave Pharms and is included in one NDA. It is available from two suppliers. There are seven…. The post New patent for Nextwave Pharms drug QUILLICHEW ER appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for MINOLIRA Minolira is a drug marketed by Epi Hlth and is included in one NDA. The generic ingredient in MINOLIRA is minocycline hydrochloride. Additional details…. The post New patent for Epi Hlth drug MINOLIRA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Annual Drug Patent Expirations for CLEVIPREX Cleviprex is a drug marketed by Chiesi and is included in one NDA. It is available from two suppliers. There are three patents protecting…. The post New patent for Chiesi drug CLEVIPREX appeared first on DrugPatentWatch - Make Better Decisions.
This chart shows the pharmaceutical companies with the most tentative generic drug approvals in 2020 The Food and Drug Administration (FDA) grants tentative approvals to generic entrants when their generic…. The post Generic companies with the most tentative approvals appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for OLINVYK Olinvyk is a drug marketed by Trevena and is included in one NDA. There are three patents protecting this drug. This drug has thirty-five…. The post New patent for Trevena drug OLINVYK appeared first on DrugPatentWatch - Make Better Decisions.
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. The engineered cells reduced inflammation and prevented a type of damage to bone, known as bone erosion, in a mouse model of rheumatoid arthritis.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: Morgan Stanley Annual Global Healthcare Conference on Wednesday, September 15 at 12:30pm ET. The live webcast can be accessed at the company’s investors page at investors.gilead.com. The replay will be available for at least 30 days following the presentation.
Cambridge, MA.— Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference. The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at investors.biogen.com. An archived version of the webcast will be available following the presentation.
This chart shows the drugs with the most patents in Slovenia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Slovenia? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for BELRAPZO Belrapzo is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Eagle Pharms drug BELRAPZO appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Annual Drug Patent Expirations for COMETRIQ Cometriq is a drug marketed by Exelixis and is included in one NDA. It is available from one supplier. There are three patents protecting…. The post New patent for Exelixis drug COMETRIQ appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for BENDEKA Bendeka is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are fifteen patents…. The post New patent for Eagle Pharms drug BENDEKA appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for CABOMETYX Cabometyx is a drug marketed by Exelixis Inc and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Exelixis Inc drug CABOMETYX appeared first on DrugPatentWatch - Make Better Decisions.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and MedinCell (Euronext: MEDCL) announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration (FDA).
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Eli Lilly and Company (NYSE: LLY) will participate in Citi’s 16th Annual BioPharma Virtual Conference on September 8 and 9, 2021. Anat Ashkenazi, senior vice president and chief financial officer, will participate in a virtual fireside chat on Thursday, September 9 at 9:45 a.m., Eastern Time. A live audio webcast will be available on the “Webcasts & Presentations” section of Lilly’s Investor website at [link].
today announced a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. The U.S. Food and Drug Administration (FDA) has converted this indication from an accelerated to a full (regular) approval. In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for any platinum-
This chart shows the pharmaceutical companies with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for BALVERSA Balversa is a drug marketed by Janssen Biotech and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Janssen Biotech drug BALVERSA appeared first on DrugPatentWatch - Make Better Decisions.
Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC). The most severe form of COVID-19 is severe respiratory failure, which requires intubation and is associated with a high mortality rate.
Late-breaking abstract highlights a network meta-analysis on monthly migraine day reductions with AJOVY, Nurtec ® ODT (Rimegepant) and Atogepant in the preventive treatment of episodic migraine. TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)– Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY ® (fremanezumab-vfrm) Injection at the International Headache Society and European Hea
Annual Drug Patent Expirations for INCIVEK Incivek is a drug marketed by Vertex Pharms and is included in one NDA. There are three patents protecting this drug. This drug has…. The post New patent expiration for Vertex Pharms drug INCIVEK appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for XIFAXAN Xifaxan is a drug marketed by Salix Pharms and is included in two NDAs. It is available from three suppliers. There are twenty-seven patents…. The post New patent for Salix Pharms drug XIFAXAN appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
97 
Let's personalize your content